Oncology

Reid Merryman, MD, discusses the potential for minimal residual disease (MRD) to inform treatment decisions, identify lymphoma subgroups, and infer gene expression.

Disease-related factors include several prognostic scoring systems, such as DIPSS, whereas patient-related factors involve age, comorbidities, spleen size, and anemia.

Surprisingly, those with overweight BMI at diagnosis did not have a poor prognosis.

Stefan Barta, MD, MS, MRCPCUK, discusses the potential role of biomarkers in predicting treatment outcomes, the emerging use of CAR T-cell therapy, and the benefits and challenges of combination therapies in managing T-cell lymphoma.

Previously, the FDA granted fast track designation to ABD-147 (Abdera Therapeutics Inc) for extensive stage small cell lung cancer.

Sonali Smith, MD, discusses T-cell–directed therapies for indolent B-cell lymphoma, focusing on their efficacy, FDA-approved treatments, and treatment challenges, such as managing cytokine release syndrome.

Rather than “trial-and-erroring” transplants for patients, experts should instead select transplants that are precise, personalized, and predictable.

OBX-115 could offer further treatment options for individuals with advanced or metastatic melanoma by enhancing persistence, antitumor activity, and clinical safety of TIL cell therapy.

The authors stress that health care providers should explain false positive results to their patients, reassure them that results may be negative, and stress the significance of continued screenings.

These companion diagnostics are poised to provide simpler and detailed insights into a patient’s genomic alternations, which could improve outcomes for patients with prostate cancer.

Jose Tinajero, PharmD, BCOP, discusses the results of a retrospective study evaluating patients with B-cell acute lymphoblastic leukemia.

Patients with DLBCL on Medicaid had worse survival outcomes than those on commercial insurance, but there were no statistically significant differences in survival between races.

Mary McGann, PharmD, BCOP, offers insights into CAR T-cell therapy and the crucial role of pharmacists in mitigating resistance.

The risk of late-stage diagnosis was higher for Asian, Black, and Native Hawaiian or Other Pacific Islander adolescent and young adult patients with cancer.

Pharmacists support treatment adherence as well as monitor adverse effects, drug-drug interactions, and quality of life.

Mirdametinib is an oral, allosteric small molecule MEK inhibitor to treat pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

In survivors of lymphoma with fragmented transition of care, preparedness and activation for the next phase of their survivorship was lacking.

Pharmacists play a crucial role in supporting patients with HR+/HER2– breast cancer.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

With diagnostic tools, oncology pharmacists and other health care providers can help to identify treatments that have the best probability of working for a specific patient.

Pharmacists have been shown to contribute to improved adherence rates, therapy optimization, patient safety, and cost-savings.

The indication is for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least 2 prior lines of therapy.

Patients can face barriers to BCMA-targeted treatments.

Aligning with previous data, the drug combination was modestly effective in patients with large B-cell lymphoma pre- and post-CAR-T-cell therapy.

The financial burden has increased significantly since 2015.

The proposed diagnostic agent has a long half-life, enables imaging the next day, and correlates to a longer shelf life in the pharmacy.

Bendamustine resulted in a greater risk of treatment complications in patients with lymphoma.

The FDA assigned the combination a Prescription Drug User Fee Act goal date of April 21, 2025.

The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.

Vimseltinib (Deciphera Pharmaceuticals) has a Prescription Drug User Fee Act goal date of February 17, 2025.